• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Industry Briefs

Industry Briefs

August 12, 2019

WCG Clinical Announces Acquisition of PharmaSeek

WCG Clinical has acquired clinical trial services organization PharmaSeek LLC, including its PFS Clinical and PatientWise subsidiaries, WCG announced last week.

Madison, Wisconsin-based PharmaSeek provides trial administration support and consulting as well as patient recruitment and training services. The company serves trial sites, multi-specialty practices, integrated health systems and academic medical centers.

Probability Platform Helps Predict Trials’ Regulatory Success

Evaluate Ltd. has developed an algorithm to predict the regulatory success of investigational drug products by combining industry and market data with individual products’ specific characteristics.

Called Product Specific PTRS, the tool aims to help sponsors evaluate the viability of their drug candidates and determine those that are not likely to make it through regulatory approval.

The tool is integrated with the company’s EvaluatePharma Vision service, which provides forecasting data, clinical timelines and sales predictions.

Javara Teams with Local Practice to Bring Trials to Patients

North Carolina-based clinical research organization Javara is teaming with a local medical practice to involve it in clinical trials that meet its patients’ needs.

Javara will place trial coordinators in Charlotte, N.C.-area Tryon Medical Partners clinics to help identify specific trials Tryon patients can participate in. Beginning in two of Tryon’s eight locations next month, Javara initially will focus on trials in endocrinology, internal medicine and dermatology and hopes to grow to 35 to 45 trials in the next 18 months.

Tryon’s 89 internists and specialists serve approximately 110, 000 patients.

FDA Releases Guidance on Drug Development for Fabry Disease

The FDA has okayed the use of a single trial to prove efficacy of any drug developed to treat Fabry Disease, according to a draft guidance the agency issued last week.

Sponsors should think about combining multiple clinical outcomes in their assessments given FD’s multi-systemic nature, highly variable rate of progression and heterogeneity, advises the guidance which focuses on trial design, efficacy endpoints and eligibility criteria.

If the drug is meant to slow or arrest disease progression but not reverse it, the trial should last long enough to observe disease progression in the control group, the guidance says.

Eligible patients should have the diagnosis confirmed through both biochemical testing and molecular genetic testing, and sponsors should think about enrolling pediatric patients in trials as early as possible.

Comments on the draft guidance are due by October 7.

Read the draft guidance here: https://bit.ly/2ZEHbWK.

Sarepta’s “Erroneous” AER Proves Costly

Sarepta Therapeutics’ stock plummeted 12.6 percent Thursday following an adverse event report (AER) of a serious side effect during a phase 2 gene therapy trial – but the company says the AER was wrongly submitted.

The sponsor says that neither it nor the trial’s principal investigator reported an adverse event involving a participant who experienced rhabdomyolysis. The participant in Sarepta’s trial, which is testing a micro-dystrophin gene therapy candidate for Duchenne muscular dystrophy, was hospitalized for observation and determined to be asymptomatic.

“While Sarepta and its principal investigator remain blinded to the study,” the company says, “the study drug safety monitoring board is unblinded to the event and has reviewed the issue and recommends the study continue uninterrupted.”

The submitter of the AER has not been identified.

Veristat Opens Office in Taiwan

Veristat has opened a new facility in Taipei, Taiwan, for its clinical trial, biostatistics and programming operations.

The new location will house a team of statistical programmers and clinical trial professionals to meet the increasing demand for local and international regulatory submission support in the region.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing